-
Gilead advances next-generation CAR-T therapies in partnership with cell therapy companies
Time of Update: 2022-11-05
Gilead announced that its subsidiary Kite has partnered with Refuge, a company dedicated to developing smart cell therapies using genetic engineering technology Biotechnologies entered into a global licensing agreement, and Kite received an exclusive license to Refuge's intellectual property for blood cancer treatment, as well as a synthetic gene expression library for that indication.
-
The first senile blood cancer CAR-T and the second indication of Gilead Tecartus were approved by the U.S. FDA
Time of Update: 2021-10-21
Recently, another indication for Gilead's cancer cell therapy Tecartus has been approved by the US FDA for the treatment of adult elderly acute lymphoblastic leukemia .
In March 2021, the US FDA approved Yescarta's second indication, which is mainly used for second-line or above treatment of adult patients with relapsed/refractory follicular lymphoma (FL) .
-
Gilead vs. Bristol-Myers Squibb's $1.2 billion CAR-T patent case reversed
Time of Update: 2021-09-13
S. Court of Appeals overturned the previous judgment and ruled that Gilead Yescarta does not need to pay Bristol-Myers Squibb the 1.
2 billion CAR-T patent infringement case, the core products and technologies involved are mainly concentrated in Yescarta, a subsidiary of Gilead, and Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, which targets CD19 CAR-T technology .
-
ASCO 2021: Gilead/Kite’s second commercial CAR-T product shows positive treatment results for new indications
Time of Update: 2021-06-17
Data from the key ZUMA-2 clinical trial showed that the overall response rate (ORR) of a single infusion of Tecartus in MCL patients was as high as 93%, and the complete response rate (CR) was 67% .
-
The world's fifth CAR-T is approved, BMS and Gilead each have two equal shares, Novartis is surpassed
Time of Update: 2021-04-19
On March 27, the FDA official website announced that it had approved Abecma, the first CAR-T cell therapy targeting BCMA for the treatment of multiple myeloma (MM) in adults.
Abecma is a CAR-T cell therapy targeting B cell maturation antigen (BCMA) jointly developed by bluebird bio and Celgene.
-
Express | 74% of patients have sustained remission for more than 18 months, and Gilead's CAR-T therapy gains the third indication
Time of Update: 2021-03-23
▎Kite Pharma, an editor of WuXi AppTec's content team, recently announced that the US FDA has accelerated the approval of the CAR-T therapy Yescarta (axicabtagene ciloleucel) as an extended indication for the treatment of relapsed/refractory follicular lymphoma (FL) Adult patients.
-
Gilead's CAR-T therapy gains third indication
Time of Update: 2021-03-22
544px;text-align:justify;white-space:normal;color:#444444;font-family:"Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;font-size:14px;background-color:#FEFEFE;box-sizing:border-box ;'> Patients with health care professionals provisions Yescarta therapy can work with kite Konnect 5em;vertical-align:inherit;box-sizing:border-box ;overflow-wrap:break-word ;">® , integrated technology platform, provide information and assist in the commercialization of CAR regressed treatment throughout the course of treatment of kites, including the production and shipments Courier tracking for status updates.
-
Gilead's CAR-T therapy won a third adaptation; the Nobel Prize-winning founding company completed the first editing of bone marrow cells in CRISPR
Time of Update: 2021-03-21
Recently, Eli Lilly and Company announced that the latest results of phase 3 clinical trials showed that neutralizing antibodies bamlanivimab (LY-CoV555, 700 mg) and etesevimab The combination therapy (LY-CoV016, 1400 mg) can reduce the risk of hospitalization or death of early high-risk COVID-19 patients by 87%.
-
CD19 CAR-T therapy! Gilead Yescarta's use of corticosteroids before infusion can reduce cytokine release syndrome and neurological events!
Time of Update: 2021-02-27
In the ZUMA-1 trial of a new safety management queue (queue 6), the primary purpose was to assess the effects of preventive use of corticosteroids and early use of corticosteroids and/or tocilizumab (toad monoantigen) therapy on the occurrence and severity of cytokine release syndrome (CRS) and neural events.
-
NICE has identified NHS England as funding Gilead's CAR T cell therapy
Time of Update: 2021-02-26
We will now continue to work closely with NHS England to prepare services to deliver this treatment to the patients most in need across the country as quickly as possible.
-
CD19 CAR-T Cell Therapy! Gilead Yescarta Treatment Recurrence/Difficult Inert Non-Hodgkin's Lymphoma (iNHL): Total remission rate of 92%!
Time of Update: 2020-12-18
data released at the ASH Annual Meeting showed that after receiving Yescarta's single infusion treatment, the medium follow-up was 17.5 months: 92% of the 104 patients with assessable efficacy were in remission (ORR-92%) and 76% were fully relieved (CR-76%).
-
CD19 CAR-T Cell Therapy! Gilead Yescarta's first-line treatment of high-risk large cell lymphoma (LBCL) has a complete remission rate of up to 74%!
Time of Update: 2020-12-18
"Yescarta, approved by the FDA in October 2017, is the first CAR-T cell therapy to treat adult patients with relapsed or refractic large B-cell lymphoma (LBLC) Treatment in adult patients with therapeutic LBCL includes diffuse large B-cell lymphoma (DLBCL), primary vertical large B-cell lymphoma (PMBCL), high-level B-cell lymphoma (HGBL), and DLBCL (i.e., transformed FL, TFL) derived from fable lymphoma (FL).
-
Gilead 2nd CAR-T Therapy Submits Listing Application for Treatment Set Cell Lymphoma
Time of Update: 2020-05-31
Set cell lymphoma is a rare non-Hodgkin's lymphoma characterized by highly invasive and poor prognosis, mainly in the elderly male population over 60 years of age Clinical manifestations of lymph node
-
Gilead car-t therapy yescarta sales performance disclosure in 2019
Time of Update: 2020-02-12
Recently, Gilead announced the company's financial report revenue in 2019 According to the financial report information, the company's total revenue in 2019 was $22.4 billion, an increase of 1.5% comp
-
Gilead 2019 financial report: hepatitis C decline, hepatitis B drug vemlidy gradually become a new force! Expansion fulcrum of car-t oncogenic business
Time of Update: 2020-02-05
On February 4, Geely announced its 2019 results, with a total annual revenue of $22.449 billion, an increase of 1.5% compared with 2018 Among them, the sales revenue of AIDS products reached US $16.43